How to access Adbry for moderate-to-severe atopic dermatitis from Dubai: 2026 emirate-level pathway via Dubai dermatology and pharmacy supply

*Clinically reviewed by Reserve Meds AI Clinical and Regulatory Review (see /trust). Last reviewed 2026-05-20.

Dubai has one of the largest dermatology service footprints in the region. Mediclinic City and Mediclinic Parkview, American Hospital Dubai, NMC Specialty Hospital, Aster Hospitals across Dubai and Sharjah, Saudi German Hospital Dubai, the Dr Sulaiman Al Habib network in Dubai, King's College Hospital London Dubai, and the major private dermatology clinics across Dubai Healthcare City and Jumeirah all treat moderate-to-severe atopic dermatitis from topical regimens through systemic immunosuppressants and into the biologic era. Public sector dermatology under Dubai Health Authority serves Emirati nationals through Rashid Hospital and the DHA primary care network. Dupixent (dupilumab) has been the most-prescribed biologic for atopic dermatitis in Dubai. Adbry (tralokinumab-ldrm) is the IL-13-selective alternative, registered with the Emirates Drug Establishment and increasingly part of the dermatologist's biologic shortlist. For a Dubai-resident adult or adolescent (12+) with moderate-to-severe AD that has plateaued on topical prescription therapy, the operational question is which biologic fits the case, how the prescription is dispensed in-emirate, and how insurance and out-of-pocket exposure work for the multi-year treatment course.

This page explains how the pathway works in 2026 for a Dubai-resident patient.

Why Adbry, and why now

Adbry is tralokinumab-ldrm, a fully human IgG4 monoclonal antibody that selectively binds to and neutralises the IL-13 cytokine itself. Developed by LEO Pharma. The mechanism distinguishes Adbry from Dupixent: Dupixent blocks the IL-4Rα receptor and inhibits both IL-4 and IL-13 signalling; Adbry binds IL-13 directly and produces selective IL-13 blockade.

FDA approved Adbry for adults December 2021, expanded to adolescents 12-17 December 2023. Pivotal trials (ECZTRA 1, 2, 3, 6) showed EASI-75 response rates 25 to 56 percent at week 16.

For a Dubai patient who has cycled through topical corticosteroids, topical calcineurin inhibitors, perhaps short courses of oral cyclosporine, and possibly a dupilumab trial that did not achieve adequate response, Adbry is the IL-13-selective alternative.

What Adbry is, in plain language

Subcutaneous injection. No infusion centre, no inpatient stay. After initial training, the patient self-injects at home. Prefilled syringe 150 mg per millilitre.

Adult dosing: 600 mg loading at week 0, then 300 mg every 2 weeks. Patients under 100 kg achieving IGA 0 or 1 at week 16 may step down to 300 mg every 4 weeks. Adolescent (12-17): 300 mg loading, then 150 mg every 2 weeks.

Taken for as long as it controls the disease, typically years for responders.

Eligibility at a Dubai dermatologist's clinic

1. Confirmed moderate-to-severe AD (EASI 16+, IGA 3+, BSA 10%+, or DLQI elevation). 2. Documented prior topical prescription therapy failure or contraindication. 3. Age 12+, weight 40 kg+. 4. Screening for active infection, especially helminthic. 5. Tuberculosis screening per institutional standard. 6. Baseline ophthalmology assessment for patients with conjunctivitis history. 7. Vaccination status review; avoid live vaccines during treatment. 8. Pregnancy planning discussion for women of childbearing potential.

Dubai prescribing and supply picture, plainly

Adbry is registered with the Emirates Drug Establishment. Commercial supply runs through LEO Pharma's regional distributor network. The pathway is:

1. Prescribing dermatologist: any board-certified Dubai dermatologist. Major Dubai dermatology services include Mediclinic City and Parkview, American Hospital Dubai, NMC Specialty Hospital, Aster Hospitals, Saudi German Hospital Dubai, Dr Sulaiman Al Habib network, King's College Hospital London Dubai, and the major private dermatology clinics across Dubai Healthcare City and Jumeirah. Public sector dermatology under DHA serves Emirati nationals. 2. Pharmacy dispensing: hospital pharmacy or community pharmacy with cold-chain refrigeration. Storage 2-8 degrees Celsius; up to 14 days at room temperature. 3. Insurance pre-authorisation: Saada and Enaya coverage for Emirati nationals, Daman, Oman Insurance, AXA Gulf, MetLife, Cigna, and other commercial insurers require documented severity and prior-therapy failure. Some require dupilumab trial-and-failure before approving tralokinumab. 4. Self-injection training: single supervised session at the prescribing dermatologist's clinic or a LEO nurse educator visit. 5. Ongoing monitoring: dermatology follow-up at weeks 4 and 16, then every 3-6 months.

The 2026 pathway, step by step

Week 0 to 1: Documentation pack with the treating dermatologist's office.

Week 1 to 4: Insurance pre-authorisation review.

Week 4 to 6: First dispensing. Loading dose 600 mg in clinic with self-injection training.

Ongoing: Self-injection every 2 weeks at home. Dermatology follow-up at weeks 4 and 16.

Week 16 onwards: Response assessment. Step-down to every-4-week dosing for responders under 100 kg with IGA 0 or 1.

Ongoing: Maintenance for as long as Adbry controls the disease.

Cost expectation in AED

US list price approximately USD 1,810.87 for a 2-syringe pack, USD 3,621.73 for a 4-syringe pack. Annual cost at list price approximately USD 25,700 to 35,000. At 2026 indicative cross rates, the AED-equivalent annual cost band is approximately AED 94,000 to 129,000 at list price.

For Emirati nationals with Saada or Enaya coverage, financial pre-authorisation needs to start before the first dispensing. Commercial cover varies.

What to monitor

Conjunctivitis is the most common adverse event, generally mild to moderate. Less common: keratitis. Baseline ophthalmology for patients with prior conjunctivitis history.

Injection-site reactions are common and typically resolve.

Live vaccines should be avoided during treatment.

Long-term safety data is reassuring through years 3 to 4 of continuous use.

Religious, ethical, and family-logistics framing

Adbry is a recombinant IgG4 monoclonal antibody produced in CHO cell lines. No donor element, no human or animal source material, no foreign genetic content. The classical analogy to vaccines holds in Emirati Islamic medical ethics.

The self-injection element is the practical pressure point for some Dubai families. Patients uncomfortable with home injection can request clinic-administered dispensing.

For adolescent patients, parental involvement in the injection routine is typical and culturally expected.

The chronic-treatment nature means a years-long routine. Plan for cold-chain pharmacy access (Dubai community pharmacies handle this well), travel-friendly storage (14-day room-temperature window), and dermatology follow-up cadence.

When Adbry is not the right call

For a Dubai patient where biologic eligibility thresholds are not met, where helminthic screening is positive, or where insurance pre-authorisation requires dupilumab trial first:

- Dupixent (dupilumab): most established MENA experience. - Ebglyss (lebrikizumab): another IL-13 antagonist. - Cibinqo (abrocitinib) and Rinvoq (upadacitinib): oral JAK1 inhibitors. - Continued topical therapy with adjuncts.

Reserve Meds does not push a default.

What Reserve Meds does on this case

We are a US-based concierge coordinator. We are not the prescriber and not the dispensing pharmacy. On a Dubai Adbry case we build the documentation pack with the treating dermatologist's office, run the insurance pre-authorisation conversation alongside the clinical pre-authorisation conversation, coordinate the cold-chain supply logistics, organise self-injection training and ophthalmology baseline if needed, and stay with the case through the first year of dosing. Clinical decisions remain with your treating dermatologist.

---

Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating dermatologist.

Clinical and regulatory review: Reserve Meds AI Clinical and Regulatory Review (see /trust). Last medically reviewed: 2026-05-20.